Introduction
============

The rising incidence of fungal infections is an emerging serious health problem, especially in cases of immune compromised patients caused either by diseases like AIDS, or by cancer therapies and prolonged antibiotic treatments ([@B22]; [@B51]). Estimates of global mortality rates suggest that fungi are responsible for more deaths than either tuberculosis or malaria ([@B9]). Millions more suffer from severe illness caused by chronic or allergic fungal infections. *Candidiasis* is the most prevalent fungal disease worldwide difficult and extremely costly to treat ([@B52]). The available antifungal drugs like polyenes, pyrimidines, azoles, and echinocandins often provoke significant toxicity including fever, nausea and vomiting, dose-limiting nephrotoxicity, liver toxicity, and controversial interactions with co-administered drugs ([@B13]; [@B53]). Another crucial problem is represented by the increasing rate of drug resistance that invalidates the clinical treatments. The alarming gap in the anti-fungal pipeline makes the discovery of new active compounds a priority for the scientific community. The strong request of new classes of compounds has renewed the interest in the screening of natural products ([@B1]; [@B4]). Especially, ethnobotany represents an important guide in the search of novel antifungal agents. Due to their ability to synthesize a limitless variety of chemical structures, plants have represented a source of bioactive remedies for centuries ([@B2]). Despite of this, it is estimated that only a small proportion of plants are used by humans. Therefore, bioactivity screening programs and research on new plant-derived compounds are of prime importance for the search of novel leads. Plants belonging to the genus *Hypericum*, are characteristic components of the European flora. In particular, Europe and the Mediterranean basin represent a hot spot of diversity for *Hypericum* species ([@B26]). The best characterized species is *H. perforatum* L., which was already described by Hippocrates as a remedy against possession in the Ancient Greece ([@B14]). During the centuries it has been used for the treatment of various pathological states, like neurological disorders, wounds, inflammations, and infections. The use of *H. perforatum* extracts is so popular that this species is considered the most important medicinal plant of the 20th century ([@B19]). The German Commission E approved its usage for several indications, including treatment and post-therapy of acute and contused injuries, myalgia and first-degree burns as well as dyspeptic complaints ([@B3]). In the Balkan Countries it is considered as one of the oldest remedies and in the Serbian folk medicine it is indicated for the treatment of cuts, burns, hemorrhoids and also as an antiseptic, for liver and stomach complaints, diarrhea, and gastric ulcers. Its sale represents a huge part of the overall herbal market ([@B11]), exceeding \$570 million/annum worldwide ([@B5]). Regarding its antifungal potential, inhibitory properties against *Candida* spp., ([@B48]) and fungal plant pathogens ([@B11]) have been reported. Nevertheless, a growing number of scientific evidences underlines the importance to investigate other *Hypericum* species that might exert a more promising antifungal activity ([@B34]; [@B44]). In this regard the species *H. carinatum, H. myrianthum, H. linoides* ([@B6]), *H. garciae* ([@B47]) have been shown to have the potential to inhibit the growth of *Candida* spp. *Cryptococcus neoformans* and *Rhodotorula mucilaginosa* growth.

In Central and Eastern Europe several different *Hypericum* species co-occur and the area is considered a significant source of plant material for the market of herbal products ([@B33]).

Amongst others, *H. maculatum* Crantz subsp. *maculatum, H. hircinum* L. s. lat., *H. hirsutum* L., and *H. montanum* L., as plants used to treat wounds, skin inflammations and burns ([@B25]), as well as infections of the respiratory ([@B38]) and urinary tract ([@B41]). These pathologies are often caused by fungi, with *Candida* as the main causative agent and by dermatophytes in the case of external infections ([@B8]; [@B21]; [@B37]). To screen for new candidates suitable for the development of novel antimycotic solutions, we studied extracts deriving from the aerial parts of several *Hypericum* taxa (*H. perforatum* L., *H. maculatum* Crantz subsp. *maculatum, H. hircinum* L. s.lat., *H. hirsutum* L., and *H. montanum* L.) with respect to their chemical profile, their antifungal activity against a broad panel of clinical fungal isolates of the human gut and their toxicological safety on human skin fibroblasts and peripheral blood mononuclear cells (PBMCs).

Materials and Methods {#s1}
=====================

Plant Material
--------------

Samples of *H. hirsutum* subsp. *hirsutum, H. hircinum* subsp. *majus, H. maculatum, H. montanum*, and *H. perforatum* have been collected during spring-summer of 2015 in the Alpine region (Northern-Eastern Italy). Species were identified according to the most recent Flora of Italy ([@B30], [@B31]), nomenclature follows [@B7] and type specimens were deposited in the Department of Food Quality and Nutrition at the Fondazione Edmund Mach in San Michele all'Adige, Trento, Italy (Reference number: NT0001 *H. perforatum*, NT0002 *H. montanum*, NT0003 *H. maculatum*, NT0004 *H. hirsutum*, NT0005 *H. hircinum* subsp. *majus*).

Preparation of Crude Plant Extracts
-----------------------------------

For each species, 500 mg of dried plant biomass, represented by stems and leaves, were powdered by grinding and extracted in the dark with methanol (drug/solvent ratio = 1:20 w/v) by maceration (3 × 24 h). *H. hircinum* subsp. *majus* was also subjected to extractions with boiling water (100°C) for 20 min, and ethanol 80% by maceration for 24 h. The obtained extracts were evaporated to dryness, weighed and stored at -20°C until analysis.

Preparation of Samples for Chemical Analysis
--------------------------------------------

Prior to analysis methanolic extracts were resuspended in 50% methanol/water and filtered using sterile (0.2 μm) PTFE filters.

LC-MS Analysis
--------------

Analysis of phenolic metabolites was performed using a Waters Acquity UPLC system (Milford, MA, United States) which consists of a binary pump, an online vacuum degasser, an autosampler and a column compartment as previously described ([@B50]). Phenolic compounds were separated at a temperature of 40°C on a Waters Acquity HSS T3 column 1.8 μm, 150 mm × 2.1 mm (Milford, MA, United States). The mobile phase was composed of component A (0.1% formic acid in water) and component B (0.1% formic acid in acetonitrile). Acetonitrile was of LC-MS grade and was purchased from Sigma--Aldrich (St. Louis, MO, United States). Pure standards of hypericin from *Hypericum perforatum* ∼95% (HPLC), hyperoside and hyperforin were purchased from Sigma-Aldrich (St. Louis, MO, United States). Milli-Q water was used for the chromatography. The flow was set to 0.4 mL/min, and the gradient profile was: 0 min, 5% B; from 0 to 3 min, linear gradient to 20% B; from 3 to 4.3 min, isocratic 20% B; from 4.3 to 9 min, linear gradient to 45% B; from 9 to 11 min, linear gradient to 100% B; from 11 to 13 min, wash at 100% B; from 13.01 to 15 min, the re-equilibrated to the initial conditions of 5% B. Analysis of hypericin, hyperforin and hyperoside was performed using the same Waters Acquity UPLC system (Milford, MA, United States) and conditions, by means of a different gradient. The gradient profile in this case was: 0 min, 10% B; from 0 to 4,5 min, linear gradient to 100% B; from 4,5 to 12 min, isocratic 100% B; finally the column was re-equilibrated to the initial conditions of 10% B for 4 min. MRM transitions for hypericin, hyperforin and hyperoside are reported in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. Each sample was analyzed in triplicate. Samples were kept at 6°C during the analysis. Mass spectrometry detection for both methods was performed on a Waters Xevo TQMS (Milford, MA, United States) instrument equipped with an electrospray (ESI) source. Capillary voltage was 3.5 kV in positive mode and -2.5 kV in negative mode; the source was kept at 150°C; the desolvation temperature was 500°C; cone gas flow, 50 L/h; and desolvation gas flow, 800 L/h. Further MS parameters are reported in [@B50].

Data Analysis
-------------

Quantification was done using Waters MassLynx 4.1 and TargetLynx software.

Microorganisms and Media
------------------------

For antifungal susceptibility testing, the reference strain *C. albicans* ATCC MYA-2876 from the American Type Culture Collection (ATCC), Rockville, MD, United States was used. The human gut clinical isolates, *C. albicans* YN7, *C. parapsilosis* YB1, *C. parapsilosis* YB3 (Di Paola et al., unpublished), *C. albicans* YHS254, *C. albicans* YHS89, *C. lusitaniae* YHS217, *C. lusitaniae* YHS72, *C. parapsilosis* YHS133, *C. parapsilosis* YHS312, *C. parapsilosis* YHS301, *Aspergillus glaucus* YHS165, *Penicillium paneum* YHS245 ([@B45]), *C. glabrata* MFB004, *C. tropicalis* MFB035-1, *C. tropicalis* RTT037-3 (Strati et al., unpublished) were tested for their susceptibility against the applied drugs. All strains were grown on Sabouraud agarized medium for 48 h at 30°C before testing.

Antifungal Susceptibility Testing
---------------------------------

*Candida* strains were tested for their susceptibility to *Hypericum* spp. extracts (7 dilution series, ranging from 500 to 8 μg/ml) following the European Committee for Antimicrobial Susceptibility Testing protocol (EUCAST DEFINITIVE DOCUMENT EDef 7.2 Revision; [@B16]). Briefly, cells were grown in RPMI1640 medium supplied with 2.0% glucose, counted and inoculated at a concentration of 1--5 × 10^5^ CFU/ml. MIC~50~ and MIC~90~ values were determined at 530 nm using a spectrophotometer, as the lowest concentration of the drug that resulted in ≥50% and ≥90% inhibition of growth relative to the growth control after 48 h incubation.

PBMC Isolation
--------------

Peripheral blood mononuclear cells were obtained from buffy coat of healthy donors (as approved by the Ethical Committee of the local health centre, Azienda Provinciale per I Servizi Sanitari, Provincia Autonoma di Trento) within 4 h from sample collection. PBMC isolation was performed using Lympholite (CEDARLANE) density gradient (1.077 g/liter, pH 6,9), according to manufacturer's instructions, and incubated in complete nutrient RPMI 1640 medium (Euroclone) supplemented with glutamine (2 mol/L), 10% fetal calf serum (FCS) and antibiotics (10000 U/ml Penicillin, 10000 μg/ml Streptomycin) (Biological Industries), at 37°C and 5% CO2.

Cytotoxicity Assay
------------------

The cytotoxicity of *H. hircinum* subsp. *majus* infusion, methanolic and hydro-alcoholic extracts was tested using the WST-8 (4-\[3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl)-2*H*-5-tetrazolio\]-1,3-benzene disulfonate sodium salt) conversion assay. The cytotoxicity of the extracts was evaluated on two normal cell lines, namely PBMC and human foreskin fibroblast Hs27. Cells were seeded in 96-well culture plates at concentration of 5000 cells/well and incubated for 24 h before treatment with *H. hircinum* subsp. *majus* extracts. Plant extracts were diluted in DMSO and added to a final concentration of 500 μg/ml (final volume of DMSO 0,5% v/v). To measure the cytotoxic effects 10 μl of Cell Counting Kit-8 (Sigma-Aldrich) (containing the WST-8 solution) were added to each well and incubated for 2--4 h for fibroblasts and PBMCs, respectively, at 37°C before reading the absorbance at 450 nm.

The results were analyzed by Student's *t*-test. The data are expressed as the percentage of viability and standard error of the mean.

Microscopy
----------

To estimate the impact of plant extracts on cell morphology and health, cultures were visualized and recorded using an inverted microscope Motic AE31 equipped with a camera Moticam 580 5.0 MP.

Results
=======

Extract Composition
-------------------

The extracts have been chemically characterized by the identification and quantification of 52 low molecular weight polyphenols belonging to the classes: flavonols, benzoates and cinnamates, chalcones, flavan-3-ols, flavones, stilbens, coumarins, phloroglucinols, and naphtodianthrones (**Table [1](#T1){ref-type="table"}**). LC-MS analysis revealed that species were characterized by different content of the detected metabolites, yet in all of the extracts, quercetin derivatives represented the most prevalent group of compounds.

###### 

Analysis of phenolic compounds in the crude extracts of *Hypericum* species.

                               *H. hirc majus*   *H. hirs*         *H. mac*          *H. mont*         *H. perf*
  ---------------------------- ----------------- ----------------- ----------------- ----------------- -----------------
  Benzoates and cinnamates     427,04 ± 47,1     45,9 ± 3,65       243,22 ± 1,14     390,72 ± 6,17     112,6 ± 10,5
  2,6-di-OH-benzoic acid       nd^∗^             nd^∗^             nd^∗^             nd^∗^             nd^∗^
  3,5-dihydroxybenzoic acid    1,78 ± 0,013      1,98 ± 0,012      1,47 ± 0,013      0,98 ± 0,009      0,96 ± 0,016
  Caffeic acid                 nd^∗^             nd^∗^             nd^∗^             nd^∗^             nd^∗^
  Cinnamic acid                nd^∗^             nd^∗^             nd^∗^             nd^∗^             nd^∗^
  Ellagic acid                 5,83 ± 0,073      3,29 ± 0,088      7,22 ± 0,114      6,25 ± 0,10       2,18 ± 0,054
  Ferulic acid                 0,06 ± 0,003      0,38 ± 0,003      0,54 ± 0,012      nd^∗^             0,26 ± 0,006
  Gallic acid                  0,70 ± 0,028      1,07 ± 0,008      0,51 ± 0,013      0,73 ± 0,032      0,42 ± 0,0013
  *p*-coumaric acid            0,08 ± 0,001      0,6 ± 0,019       0,26 ± 0,009      0,25 ± 0,002      0,23 ± 0,007
  *p*-OH-benzoic acid          nd^∗^             nd^∗^             nd^∗^             nd^∗^             nd^∗^
  Vanillic acid                nd^∗^             nd^∗^             nd^∗^             nd^∗^             nd^∗^
  Chlorogenic acid             323,03 ± 4,946    8,51 ± 0,450      nd^∗^             nd^∗^             18,92 ± 0,949
  Cryptochlorogenic acid       0,58 ± 0,009      0,12 ± 0,007      1,32 ± 0,048      4,44 ± 0,025      0,72 ± 0,01
  Neochlorogenic acid          95,07 ± 0,194     29,95 ± 0,032     231,90 ± 0,112    378,07 ± 0,449    88,91 ± 0,204
  Flavonols                    9393,64 ± 50,3    7470,05 ± 28,01   6555,52 ± 30,21   5284,31 ± 13,25   7189,19 ± 47,26
  Hyperoside                   9306 ± 385        7430 ± 211        6240 ± 488        4940 ± 66,3       6880 ± 469
  Quercetin                    2,28 ± 0,043      9,67 ± 0,063      45,44 ± 0,159     14,35 ± 0,085     5,13 ± 0,011
  Quercetin-3-arabinoside      nd^∗^             0,19 ± 0,005      32,40 ± 0,099     23,19 ± 0,047     132,86 ± 1,522
  Quercetin-3-glucoside        43,56 ± 0,536     18,12 ± 0,529     226,89 ± 1,948    235,33 ± 1,712    14,28 ± 0,479
  Quercetin-3-glucuronide      28,77 ± 0,212     nd^∗^             nd^∗^             nd^∗^             2,54 ± 0,02
  Quercetin-3-sulfate          11,91 ± 0,026     2,22 ± 0,018      4,64 ± 0,024      0,69 ± 0,004      34,82 ± 0,024
  Rutin                        nd^∗^             2,47 ± 0,031      3,19 ± 0,015      0,86 ± 0,006      118,89 ± 0,197
  Kaempferol                   0,025 ± 0,001     1,73 ± 0,007      0,43 ± 0,005      0,11 ± 0,001      0,19 ± 0,001
  Kaempferol-3-glucuronide     0,48 ± 0,0151     nd^∗^             nd^∗^             nd^∗^             0,05 ± 0,001
  Kaempferol -3-glucoside      0,38 ± 0,012      2,38 ± 0,071      2,16 ± 0,038      1,18 ± 0,031      0,33 ± 0,009
  Syringetin-3-glucoside       nd^∗^             nd^∗^             nd^∗^             nd^∗^             nd^∗^
  Iso-rhamnetin                nd^∗^             nd^∗^             0,13 ± 0,003      nd^∗^             nd^∗^
  Iso-rhamnetine-3-glucoside   nd^∗^             0,08 ± 0,004      nd^∗^             nd^∗^             nd^∗^
  Myricetin                    0,23 ± 0,004      3,19 ± 0,014      0,24 ± 0,003      0,29 ± 0,004      0,10 ± 0,002
  Flavones                     0,65 ± 0,036      2,215 ± 0,016     1,175 ± 0,006     3,035 ± 0,014     0,45 ± 0,010
  Luteolin                     trace             1,93 ± 0,011      0,79 ± 0,004      2,52 ± 0,009      0,22 ± 0,006
  Luteolin 7-O-glucoside       0,65 ± 0,036      0,28 ± 0,005      0,38 ± 0,002      0,51 ± 0,005      0,18 ± 0,004
  Flavanones                   0,44 ± 0,009      1,43 ± 0,031      0,58 ± 0,018      2,3 ± 0,009       0,82 ± 0,016
  sNaringenin                  0,05 ± 0,004      0,18 ± 0,006      nd^∗^             0,07 ± 0,002      0,10 ± 0,004
  Naringenin-7-glucoside       0,39 ± 0,005      1,25 ± 0,025      0,58 ± 0,018      2,23 ± 0,007      0,72 ± 0,012
  Chalcones                    0,11 ± 0,006      0,42 ± 0,005      0,32 ± 0,008      nd^∗^             0,31 ± 0,005
  Phlorizin                    0,11 ± 0,006      0,42 ± 0,005      0,32 ± 0,008      nd^∗^             0,31 ± 0,005
  Coumarins                    0,23 ± 0,0032     0,07 ± 0,002      0,14 ± 0,004      0,55 ± 0,005      0,22 ± 0,002
  Esculin                      0,23 ± 0,0032     0,07 ± 0,002      0,14 ± 0,004      0,55 ± 0,005      0,22 ± 0,002
  Flavan-3-ols                 53,12 ± 1,24      74,12 ± 3,12      100,09 ± 4,81     58,28 ± 1,53      59,47 ± 2,47
  Catechin                     21,94 ± 0,609     5,25 ± 0,034      3,68 ± 0,114      1,79 ± 0,048      4,21 ± 0,161
  Epicatechin                  19,28 ± 0,212     40,21 ± 0,258     68,52 ± 0,029     53,61 ± 0,166     43,76 ± 0,17
  Epigallocatechin             3,31 ± 0,030      0,42 ± 0,014      0,52 ± 0,008      1,44 ± 0,031      0,82 ± 0,025
  Gallocatechin                2,21 ± 0,032      nd^∗^             nd^∗^             nd^∗^             nd^∗^
  Procyanidin B~1~             1,37 ± 0,007      0,94 ± 0,025      0,89 ± 0,018      nd^∗^             0,42 ± 0,005
  Procyanidin B~2~             5,01 ± 0,091      27,3 ± 0,521      26,48 ± 0,770     1,44 ± 0,287      10,26 ± 0,111
  Stilbenoids                  0,06 ± 0,001      0,91 ± 0,015      2,24 ± 0,009      0,99 ± 0,008      3,32 ± 0,052
  *cis*-piceid                 0,06 ± 0,001      0,91 ± 0,015      2,24 ± 0,009      0,99 ± 0,008      3,32 ± 0,052
  Phloroglucinols              nd^∗^             nd^∗^             nd^∗^             20 ± 1,91         8050 ± 565
  Hyperforin                   nd^∗^             nd^∗^             nd^∗^             20 ± 1,91         8050 ± 565
  Naphtodianthrones            nd^∗^             30 ± 1,79         20 ± 1,71         40 ± 2,67         150 ± 25,1
  Hypericin                    nd^∗^             30 ± 1,79         20 ± 1,71         40 ± 2,67         150 ± 25,1

H. hirs majus, H. hircinum subsp. majus; H. hirs, H. hirsutum; H. mac, H. maculatum; H. mon, H. montanum; H. perf, H. perforatum.

∗

nd, not detected.

Quercetin and quercetin glycosides ranged from 5,21 mg/g in *H. montanum* to 9,4 mg/g in *H. hircinum* subsp. *majus*, with hyperoside being the major compounds in the extracts representing the 45,48% of the detected compounds in *H. perforatum* and more than the 99% in the other *Hypericum* species. Quercetin-3-glucoside was abundant in *H. maculatum* and in *H. montanum*, while quercetin 3-rhamnoside was highly present in *H. perforatum* (132,9 μg/g). Quercetin-3-glucuronide only occurred in *H. hircinum* subsp. *majus* (28,8 μg/g) and in *H. perforatum* (10-fold less concentrated). Chlorogenic acid derivatives (chlorogenic acid, neochlorogenic acid, and cryptochlorogenic acid) ranged from 38 μg/g for *H. hirsutum* and *H. perforatum* to 456,7 μg/g in *H. hircinum* subsp. *majus*. Also the flavan-3-ols were relatively abundant ranging from 53,12 μg/g in *H. hircinum* subsp. *majus* to 100,12 μg/g in *H. maculatum*, with epicatechin being the principal compound of this class (from 19 μg/g in *H. hircinum* subsp. *majus* up to 68,5 μg/g in *H. maculatum*).

Antifungal Activity of *Hypericum* Crude Extracts
-------------------------------------------------

*Hypericum* extracts were screened against a panel of clinical *Candida* isolates (**Table [2](#T2){ref-type="table"}** and Supplementary Table [S2](#SM2){ref-type="supplementary-material"}) and the results are hereafter given as GM of MIC values. The screening unveiled that *H. hircinum* subsp. *majus* crude methanolic extract had a strong anti-*Candida* activity against all tested fungal strains, with inhibition properties against *C. parapsilosis* (MIC~50~ 53,5 μg/ml) in the same magnitude of fluconazole (MIC~50~ 22,63 μg/ml).

###### 

Antifungal activity of *Hypericum* species.

  Species (strain no.)    *H. hircinum*   *H. maculatum*   *H. montanum*   *H. perforatum*   *H. hirsutum*   Fluconazole                                                           
  ----------------------- --------------- ---------------- --------------- ----------------- --------------- ------------- -------------- ---------- -------------- ------- ------ ----------
  *C. albicans* (2)       63,25           32--125          250             250               500             500           353,3          250--500   500            500     0,35   0,125--1
  C. *parapsilosis* (2)   32              32               500             500               \>500           \>500         [\>]{.ul}125   125--500   [\>]{.ul}500   500     48     32--64
  *C. tropicalis* (2)     353,55          \>500            \>500           \>500             \>500           \>500         \>500          \>500      \>500          \>500   \>64   \>64
  *C. lusitaniae* (1)     16              125              64              64                125             125           125            125        64             64      0,5    0,5
  *C. glabrata* (1)       250             \>500            \>500           \>500             \>500           \>500         \>500          \>500      \>500          \>500   0,13   0,13

Data are expressed as GM in μg/ml.

All extracts exerted antifungal properties against *C. albicans* and *C. lusitaniae* while only *H. hircinum* subsp. *majus* was also active against *C. tropicalis* and *C. glabrata* (MIC~50~ 353,55 and 16 μg/ml, respectively).

Also, with respect to the to the MIC~90~ values, *H. hircinum* subsp. *majus* extract showed higher inhibitory properties than the other tested extracts (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}).

Antifungal Activity of *H. hircinum* subsp. *majus* Extracts
------------------------------------------------------------

The antifungal activity of *H. hircinum* subsp. *majus* was further investigated against a broader panel of *Candida*, including fluconazole resistant strains, and other fungi (**Table [3](#T3){ref-type="table"}** and Supplementary Table [S3](#SM3){ref-type="supplementary-material"}). In addition to crude methanolic extract, infusion and hydroalcoholic extracts have been tested. Notably, all *H. hircinum* subsp. *majus* extracts showed antifungal properties and, in particular a remarkable activity against fluconazole resistant *C. parapsilosis* and *C. tropicalis* strains. The methanolic extract showed the most pronounced cytotoxic properties. Yet, in general the antifungal activity of the infusion outcompeted those of the hydroalcoholic extract, also with respect to the MIC~90~ values.

###### 

Antifungal activity of *H. hircinum* subsp. *majus*.

  Species (strain no.)        Methanol   Ethanol 80%   Infusion   Fluconazole                          
  --------------------------- ---------- ------------- ---------- ------------- ------- ------- ------ ------
  *C. albicans* (4)           31,81      ≥149,5        75,21      \>420,4       63,25   \>250   4      ≥9,5
  *C. tropicalis* (2)         353,55     \>500         353,55     \>500         177     \>500   \>64   \>64
  *C. parapsilosis* (5)       53,5       ≥250          250        ≥500          95,18   ≥300    ≥60    \>64
  *C. lusitaniae* (2)         16         89,4          63,25      250           32      177     0,35   1,5
  *C. glabrata* (1)           16         64            64         250           64      250     0,13   1
  *Aspergillus glaucus* (1)   \>500      \>500         \>500      \>500         250     \>500   0,25   16
  *Penicillium paneum* (1)    \>500      \>500         \>500      \>500         64      500     0,13   4

Data are expressed as GM in μg/ml.

Cytotoxicity of *H. hircinum* subsp. *majus* Extracts
-----------------------------------------------------

The cytototoxicity of *H. hircinum* subsp. *majus* extracts was tested on PBMC and human skin fibroblast Hs27 cell lines by using the WST-8 conversion assay. The extracts were tested at a dose of 500 μg/ml, which corresponds to a 1- (for *C. tropicalis*) to 10-fold higher concentration than those showing inhibition of 50% of *Candida* growth. As shown in **Figure [1](#F1){ref-type="fig"}**, only the plant infusion showed no cytotoxic effect on both human cell lines, while treatment with methanolic and hydroalcoholic extracts inhibited cell viability by 50% for Hs27 cell line and by 65--70% for PBMCs.

![Cytotoxicity of *H. hircinum* subsp. *majus* extracts (measured using the WST-8 conversion assay). The metabolic activity is given as the endpoint of toxicity in human peripheral mononucleate cells (PBMC) and human skin fibroblast cell line (Hs27), following 24 h exposure to *H. hircinum* subsp. *majus* extracts. Values represent standard error of the mean (*n* = 3); Asterisks denote statistically significant differences from control (^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01).](fphar-09-00382-g001){#F1}

The effect of *H. hircinum* subsp. *majus* on human cells was also observed microscopically (**Figure [2](#F2){ref-type="fig"}**). The imagines confirmed the cytotoxicity data. Fibroblast treated with plant infusion showed a normal phenotype, while under treatment with methanolic and hydro-alcoholic extracts the cell morphology was markedly altered. The same alteration was observed for PBMCs (data not shown).

![Morphology change of normal fibroblast Hs27 after 24 h treatment with *H. hircinum* subsp. *majus* extracts (observed under inverted microscope, magnification 100×): **(A)** control (DMSO), **(B)** methanolic extract, **(C)** hydroalcoholic extract, and **(D)** infusion.](fphar-09-00382-g002){#F2}

Chemical Composition of *H. hircinum* susbps. *majus* Infusion
--------------------------------------------------------------

The chemical composition of the aqueous extract of *H. hircinum* subsp. *majus* is reported in **Table [4](#T4){ref-type="table"}**. The analysis revealed that the infusion process allowed the extraction of higher amounts of phenols in comparison to the extraction by maceration in methanol. The aqueous extract was mainly characterized by derivatives of quercetin (24,18 mg/g), of chlorogenic acid (4,51 mg/g) and by flavan-3-ols (2,26 mg/g). Hyperoside was the most abundant compound, representing the 2,23% of the extract. Abundant were also quercetin-3-glucoside (1,65 mg/g), neochlorogenic acid (2,61 mg/g), chlorogenic acid (1,68 mg/g), procyanidin B2 (0,89 mg/g), epicatechin (0,59 mg/g) and procyanidin B1(0,40 mg/g).

###### 

Analysis of phenolic compounds in the infusion of *H. hircinum* subsp. *majus.*

  Compound                    Amount (μg/g extract)   Compound                     Amount (μg/g extract)
  --------------------------- ----------------------- ---------------------------- -----------------------
  2,6-di-OH-benzoic acid      nd^∗^**^∗^**            Kaempferol                   1,08 ± 0,15
  3,5-dihydroxybenzoic acid   7,08 ± 0,79             Kaempferol -3-glucoside      7,89 ± 1,09
  Caffeic acid                44,62 ± 4,97            Kaempferol-3-glucuronide     104,41 ± 14,49
  Coniferyl alcohol           nd^∗^                   Iso-rhamnetin                0,78 ± 0,11
  Gallic acid                 15,74 ± 2,18            Iso-rhamnetine-3-glucoside   nd^∗^
  Cinnamic acid               6,10 ± 0,85             Syringetin-3-glucoside       3,39 ± 0,46
  *p*-coumaric acid           nd^∗^                   Myricetin                    7,68 ± 1,07
  *p*-OH-benzoic acid         8,97 ± 1,24             Luteolin                     3,51 ± 0,22
  Vanillic acid               1,29 ± 0,18             Luteolin 7-O-glucoside       1,77 ± 0,24
  Cryptochlorogenic acid      229,7 ± 31,88           Naringenin                   nd^∗^
  Chlorogenic acid            1683 ± 233,7            Esculin                      21,28 ± 2,95
  Neochlorogenic acid         2615 ± 362,9            Phlorizin                    6,57 ± 0,91
  Hyperoside                  22203 ± 380             Catechin                     282,2 ± 2,71
  Quercetin                   164,38 ± 15,52          Epicatechin                  586,51 ± 68,05
  Quercetin-3-arabinoside     nd^∗^                   Epigallocatechin             55,77 ± 7,74
  Quercetin-3-glucoside       1647 ± 65,03            Gallocatechin                48,92 ± 9,72
  Quercetin-3-glucuronide     104,41 ± 14,92          Procyanidin B~1~             401,6 ± 55,74
  Quercetin-3-sulfate         nd^∗^                   Procyanidin B~2~             886,16 ± 108,77
  Rutin                       nd^∗^                   *cis*-piceid                 1,37 ± 0,19

Data are means of three independent experiments,

∗

nd, not detected.

Discussion
==========

Plant-based treatments of the traditional medicine could bring forth new solutions for antifungal therapies. In particular polyphenol-rich plants represent an import source of bioactive products for human health ([@B24]) including antifungal treatments. Among polyphenols, flavan-3-ols, flavonols and tannins show a high antimicrobial potential ([@B12]). Flavan-3-ols isolated from green and black tea exert important anti-*Candida* activity ([@B20]; [@B43]), ellagitannins obtained from *Punica granatum* inhibit the growth of plant pathogenic fungi ([@B18]), the flavonols myricitrin and fisetin are considered effective agents against *Candida glabrata* and *Cryptococcus neoformans*, respectively ([@B40]; [@B36]). The mechanisms of action of phenols against *Candida* have been intensively studied and include inactivation of enzyme production ([@B17]) and anti-biofilm effects ([@B17]; [@B42]). Species belonging to the *Hypericum* genus are able to synthesize a broad array of such bioactive phenolic compounds, mainly as products of the polyketide metabolism ([@B46]), and therefore might contain novel antifungal remedies.

Here we report new data on the inhibitory activity of extracts deriving from *H. montanum*, H. *maculatum, H. hirsutum*, and *H. hircinum* subsp. *majus* and additional data on the activity of *H. perforatum* on the growth of clinical isolates of *Candida* spp. The crude extracts obtained from *H. maculatum, H. montanum, H. hirsutum*, and *H. perforatum* showed a moderate antifungal activity against *C. albicans*, in the range of 250--500 μg/ml, good activity against *C. lusitaniae* (64--125 μg/ml) and no or only weak activity against *C. parapsilosis, C. tropicalis and C. glabrata*. Our data are in accordance with those of [@B34], showing that extracts of *H. hirsutum, H. maculatum*, and *H. perforatum* exerted comparable antifungal activity against *C. albicans* using the disk diffusion method assay. Discordant data are reported in [@B10] which found no activity of extracts obtained from *H. hirsutum* or *H. montanum* against *C. albicans*. Most interesting, the antifungal screening of crude extracts unveiled the promising anti-*Candida* properties of *H. hircinum* subsp. *majus*. The test showed that extracts obtained from this species are able to inhibit 50% of growth of *C. albicans* at concentrations that are fourfold to eightfold lower than other *Hypericum* extracts and with a more pronounced activity against *C. parapsilosis* and *C. lusitaniae*. Moreover *H. hircinum* methanolic extract was the only treatment able to inhibit the growth of *C. tropicalis* and *C. glabrata*. These results are important especially in the light of the increasing incidence of infections caused by emerging *Candida* pathogens like *C. glabrata, C. parapsilosis, C. tropicalis*, and *C. krusei*, which are less susceptible to the commonly used antifungal drugs ([@B49]; [@B28]). Previous data on the antifungal activity of *H. hircinum* are scarce and limited to susceptibility tests against just a single reference strain of *C. albicans*. Using the disk diffusion test method [@B32] found no antifungal activity against the tested strain, while [@B10] reported a higher activity of *H. hircinum* subsp. *majus* in comparison to other *Hypericum* species.

From a chemical point of view, the extracts applied as treatments in our tests have been deeply characterized by investigating the presence of 52 phenolic compounds. In general, the most abundant classes of detected compounds were flavonols, benzoate and cinnamates (chlorogenic acid and neochlorogenic acid), and flavan-3-ols. The major metabolite in all the extracts was the flavonol hyperoside, ranging from 4940 ± 66,3 μg/g in *H. montanum* to 9306 ± 385 μg/g in *H. hircinum* subsp. *majus*, and very abundant were the neochlorogenic acid and the flavan-3-ol epicatechin. Hyperoside is known for its anticancer, anti-inflammatory and antimicrobial properties ([@B27]). The extract of *H. hircinum* subsp. *majus*, showed several chemical peculiarities. It contained the highest amount of hyperoside, higher amounts of chlorogenic acid, quercetin-3-glucuronide, kampferol-3-glucuronide, catechin, epigallogatechin, gallocatechin, and no traces of the phloroglucinol hyperforin and of the naphtodianthrone hypericin.

In the light of its pronounced growth inhibition properties against *Candida* spp. and considering the ethnobotanical knowledge available for this species, *H. hircinum* subsp. *majus* has been further subjected to a deeper antifungal screen. *H. hircinum* is a shrub native to the areas of the Mediterranean Basin comprising Greece and Turkey ([@B15]). The infusion of its aerial part is applied in the traditional medicine to treat chronic catarrhal affections, asthma, sore throats and cough ([@B29]). Recent scientific evidences indicate that fungi of the phyla Basidiomycetes and Ascomycetes (e.g., *Bjerkandera, Aspergillus, Candida*, and *Saccharomyces*) are causative agents of these pathologies ([@B35]).

To investigate whether the beneficial effect of *H. hircinum* treatments may be attributed to its antifungal activity, we studied, for the first time, the activity of extracts obtained from the aerial parts of the plant with a hydroalcoholic solution and, in accordance with the traditional preparations, by infusion in boiling water. Additionally, we characterized the chemical profile. The assay was performed on a broad panel of clinical *Candida* strains, a strain of *Aspergillus glaucus* and a strain of *Penicillium paneum* (**Table [3](#T3){ref-type="table"}** and Supplementary Table [S3](#SM3){ref-type="supplementary-material"}). The extract obtained from the herbal tea inhibited 50% of the growth of all tested fungi, showing strong activity against both fluconazole sensitive and resistant *Candida* strains and moderate activity against *Aspergillus* and *Penicillium* strains. The chemical profile revealed an enrichment in the polyphenol content in comparison with the crude methanolic extract. Particularly abundant (content higher than 40 μg/g extract) were caffeic acid, chlorogenic, neochlorogenic and cryptochlorogenic acid, quercetin, quercetin-3-glucoside, quercetin-3-glucuronide, kaempferol-3-glucuronide, all the flavan-3-ols investigated and extraordinary high levels of hyperoside were detected. Even if the bioactivity may be due to the synergistic action of the phytocomplex, it appears reasonable to exclude caffeic acid, chlorogenic acid, quercetin-3-glucuronide, kaempferol-3-glucuronide, and gallocatechin as secondary metabolites to which the antifungal activity may be attributed, since these compounds are not present in the other *Hypericum* extracts showing growth inhibitory properties on *Candida* strains. Also, cryptochlorogenic acid, neochlorogenic acid quercetin, quercetin-3-glucoside, epicatechin, have been detected in all the crude extract, but they were less present in *H. hircinum* subsp. *majus* and thus their presence cannot be considered correlated to the bioactivity. According to our data a positive correlation between the amount of catechin, epigallocatechin, procyanidin B~1~ and hyperoside and the antifungal activity exerted can be individuated. The anti-*Candida* properties of flavan-3-ols, and in particular of catechin and epigallocatechin, are well known and documented ([@B20]; [@B39]). Nevertheless, our data suggest that the hyperoside, being detected in such high amounts in the extract obtained by the infusion of *H. hircinum* subsp. *majus* in water, may play a fundamental role in the observed fungal growth inhibition properties. The hypothesis is supported by studies proposing hyperoside as a lead for the development of new fungicides ([@B23]).

Finally, the aqueous extract of *H. hircinum* subsp. *majus* showed another promising characteristic exploitable for the development of a new antifungal therapy. When tested at high concentrations on human PBMCs and human skin fibroblast Hs27cell lines, no cytotoxicity was detected.

Conclusion
==========

Our work reports a comprehensive phenolic profile of five European *Hypericum* species, highlighting the presence of important exploitable bioactive metabolites. The infusion of *H. hircinum* subsp. *majus* used in the popular medicine for the treatment of respiratory tract affections has been chemically and biologically investigated for the first time. The chemical analysis unveiled a new source of the bioactive metabolite hyperoside that might be involved in the observed bioactivity of the extract. The biological tests suggest that the beneficial effects of the traditional remedies based on *H. hircinum* could be attributed to its antiseptic, and in particular to its antifungal properties against fungal pathogens of the respiratory tract. Moreover, the lack of cytotoxicity indicates the presence of exploitable and promising antimycotic principles for the development of an antifungal therapy with limited cytotoxic side effects. Hence it encourages future studies to assess the effective therapeutic properties of *H. hircinum* subsp. *majus* with particular attention to the treatment of fungal-associated pathologies of the respiratory tract.
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